Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance

BACKGROUND: Hydroxychloroquine has shown potential to block viral replication of SARS-CoV-2 in some in vitro studies. This randomised, double-blinded, placebo controlled clinical trial evaluated the efficacy of hydroxychloroquine plus azithromycin (HCQ/AZT) in reducing viral loads in patients with e...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, Cristhieni, Freitas-Santos, Rodrigo S., Levi, José Eduardo, Senerchia, Andreza A., Lopes, Ana Tarina A., Santos, Sergio R., Siciliano, Rinaldo F., Pierrotti, Lígia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386096/
https://www.ncbi.nlm.nih.gov/pubmed/34454044
http://dx.doi.org/10.1016/j.ijantimicag.2021.106428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386096/
https://www.ncbi.nlm.nih.gov/pubmed/34454044
http://dx.doi.org/10.1016/j.ijantimicag.2021.106428

Ejemplares similares